Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)

BACKGROUND: A phase II clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) as first-line chemotherapy for patients with metastatic breast cancer (MBC) found that the EG regimen was less neurotoxic, but was similar in efficacy to the PG regimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ji-Yeon, Park, Seri, Im, Seock-Ah, Kim, Sung-Bae, Sohn, Joohyuk, Lee, Keun Seok, Chae, Yee Soo, Lee, Ki Hyeong, Kim, Jee Hyun, Im, Young-Hyuck, Kim, Tae-Yong, Lee, Kyung-Hun, Ahn, Jin-Hee, Kim, Gun Min, Park, In Hae, Lee, Soo Jung, Han, Hye Sook, Kim, Se Hyun, Jung, Kyung Hae, Park, Yeon Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540535/
https://www.ncbi.nlm.nih.gov/pubmed/31138332
http://dx.doi.org/10.1186/s40880-019-0375-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540535/
https://www.ncbi.nlm.nih.gov/pubmed/31138332
http://dx.doi.org/10.1186/s40880-019-0375-7

Ejemplares similares